Silk Road Medical Inc

Silk Road Medical, Inc. develops and manufactures medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Silk Road Medical Inc reports robust Q4 performance and eyes global expansion

Silk Road Medical Inc's Q4 2022 performance reflects strong revenue growth and operational efficiency, supported by a focus on market expansion and cost management.
While facing challenges in cost control and operational metrics, the company's strategic initiatives and revenue guidance for 2023 signal growth potential.
Opportunities lie in leveraging the cash balance for growth, expanding TCAR utilization, and addressing analyst concerns to drive future success.

Silk Road Medical reports robust Q1 earnings and eyes international expansion

Silk Road Medical's Q1 2023 earnings call highlighted strong revenue growth, innovative product launches, and strategic international expansion plans.
While the company faces challenges in scaling operations and managing costs, it remains well-positioned with a solid financial foundation and a focus on driving sustainable growth.
With a clear focus on optimizing revenue per procedure and expanding geographically, Silk Road Medical is poised to capitalize on opportunities for market growth and product adoption.

Silk Road Medical Inc posts strong Q2 earnings, eyes global expansion

Silk Road Medical Inc delivered robust Q2 2023 results, showcasing revenue growth, product advancements, and strategic progress. While facing competition and regulatory challenges, the company is well-positioned to capitalize on international markets and drive further growth through operational efficiency.

Silk Road Medical posts strong Q3 results, eyes growth opportunities

Silk Road Medical's Q3 2023 earnings call highlighted robust financial performance, leadership changes, strategic initiatives, and market opportunities. The company faces challenges in sales force management and margin optimization but is well-positioned to capitalize on growth prospects.

Silk Road Medical reports robust 2023 earnings, eyes international expansion

Silk Road Medical's strong financial performance in 2023, driven by revenue growth and strategic initiatives, sets the stage for continued success.
While facing challenges such as sales force turnover and market dynamics, the company's focus on innovation and international expansion presents opportunities for growth.
Maintaining a stable pricing strategy, deepening physician adoption, and leveraging new product advancements are key to Silk Road's sustainable growth strategy.
Navigating competition in carotid treatments and maximizing the adoption curve for TCAR procedures are critical areas for Silk Road's future success.

Silk Road Medical reports robust Q1 earnings and eyes international growth

Silk Road Medical's Q1 2024 performance reflects revenue growth, improved EBITDA, and strong financial stability despite operational challenges.
The company's strengths lie in its leadership in carotid treatment, growth opportunities in international markets, and innovative product development.
Challenges include profitability concerns, margin pressure, and the need for efficient cost management amid rising expenses.
Opportunities for Silk Road Medical include market expansion, revenue growth, and continued innovation to solidify its position as a leader in carotid treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Silk Road Medical, Inc. engages in the development and manufacturing of medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.

Novo Nordisk

Shares of Thor Industries Inc. THO rose 2% after the RV maker said its board authorized a 7% dividend increase to 48 cents a share.

Novo Nordisk shares rise, Silk Road Medical stock slumps and other movers

Silk Road Medical Inc. SILK, -0.71% shares dropped in the extended session Tuesday after the medical device company updated its forecast and said its chief executive was retiring. The company forecast third-quarter revenue of about $44.4 million, and full-year revenue of $170 million to $174 million.

Silk Road Medical stock falls following outlook, CEO's retirement

SUNNYVALE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced preliminary revenue for the quarter ended September 30, 2023, and provided an update to full year 2023 revenue guidance.

Silk Road Medical Announces Preliminary Third Quarter 2023 Revenue and Provides Revised 2023 Outlook

Working with Leading Executive Search Firm to Identify Successor SUNNYVALE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that CEO Erica Rogers plans to retire from the Company following the completion of a succession process.

Silk Road Medical Announces Retirement of CEO Erica Rogers

SUNNYVALE, Calif., Sept. 04, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that management will present at the CL King 21st Annual Best Ideas Conference.

Silk Road Medical to Present at the CL King 21st Annual Best Ideas Conference

SUNNYVALE, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming UBS MedTech, Tools and Genomics Summit.

Silk Road Medical to Present at the UBS MedTech, Tools and Genomics Summit

Silk Road Medical, Inc. (NASDAQ:SILK ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations Erica Rogers - Chief Executive Officer Lucas Buchanan - Chief Financial Officer & Chief Operating Officer Conference Call Participants Chris Pasquale - Nephron Research Rick Wise - Stifel Neil Chatterji - B. Riley Joanne Wuensch - Citi Travis Steed - Bank of America Securities Kristen Stewart - CL King Adam Maeder - Piper Sandler Michael Polark - Wolfe Research Operator Good afternoon and thank you for joining Silk Road Medical's Second Quarter 2023 Earnings Call.

Silk Road Medical, Inc. (SILK) Q2 2023 Earnings Call Transcript

SUNNYVALE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2023.

Silk Road Medical Reports Second Quarter 2023 Financial Results

Aadi Bioscience

FibroGen

Inogen

Theseus Pharmaceuticals

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This MonthSilk Road Me

Shares of Silk Road Medical Inc. SILK, -20.18% tanked 21.9% toward a more-than three-year low in premarket Tuesday, after an unfavorable government decision regarding Medicare coverage of carotid artery stenting. The Centers for Medicare & Medicaid Services (CMS) proposed that coverage of percutaneous transluminal angioplasty (PTA) of carotid arteries concurrent with stenting (CAS) is “reasonable and necessary” with devices approved or cleared with the Food and Drug Administration.

Silk Road Medical stock tanks after CMS decision on carotid artery stenting prompts analyst downgrade

Domino's Pizza

Markets moved higher on favorable inflation readings. Domino's announced a delivery partnership with Uber Eats.

Domino's Is Heating Up, but This Healthcare Stock Is Looking Ill

SUNNYVALE, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the second quarter 2023 after market close on Tuesday, August 1st, 2023. Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Silk Road Medical to Report Second Quarter 2023 Financial Results on August 1, 2023

Silk Road Medical continues to grow at a solid pace, while shares continue to be under pressure. Previously awarded a >20 times sales multiple, the valuation has come down to about 6 times sales.

Silk Road Medical: Speculative Appeal Is Seen Here

This article is an investment recommendation based not on the critique of corporate productivity, competitive ability, or profit management measured by forecasts of EPS, but on communication skills. Investment achievement depends upon acceptance, by others than present owners, of the probability that per share prices can likely rise to attractive rates of gain in reasonable holding periods.

Silk Road Medical: Big Nearby Cap-Gain Medical Equipment Stock Prospect

Silk Road Medical, Inc. (NASDAQ:SILK ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Marissa Bych - IR Erica Rogers - CEO Lucas Buchanan - CFO and COO Conference Call Participants Robbie Marcus - JPMorgan Rick Wise - Stifel Adam Maeder - Piper Sandler Neil Chatterji - B. Riley Operator Good day.

Silk Road Medical, Inc. (SILK) Q1 2023 Earnings Call Transcript

Silk Road Medical (SILK) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.48 per share a year ago.

Silk Road Medical (SILK) Reports Q1 Loss, Lags Revenue Estimates

SUNNYVALE, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it has been Certified™ by Great Place To Work® for the 3rd year in a row. The prestigious award is based entirely on what current employees say about their experience working at Silk Road Medical. This year, 97% of employees said Silk Road Medical is a great place to work – a full 40 points higher than the average U.S. company. Great Place To Work® is the global authority on workplace culture, employee experience, and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation.

Silk Road Medical Receives 2023 Great Place To Work Certification™

SUNNYVALE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that the company will host an investor education webcast at 11:00 a.m. Eastern Time on Thursday, May 25, 2023. The event represents the first in a series of webcasts being organized by the company to educate investors on TCAR and the treatment of carotid artery disease.

Silk Road Medical Announces Investor Education Webcast with Key Opinion Leaders

SUNNYVALE, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming BofA Securities 2023 Healthcare Conference.

Silk Road Medical to Present at the BofA Securities 2023 Healthcare Conference

SUNNYVALE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2023 after market close on Tuesday, May 9th, 2023. Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Silk Road Medical to Report First Quarter 2023 Financial Results on May 9, 2023

“A 3-5 month prospect from here of SILK share prices could reasonably range from a $47.07 low to a $61.27 high from its $47.29 present price, a gain of +29.6%." The result of 54 positions like today's in the past 4 years of 874 market days was average net gains at 21.7% each during 51 market days (nearly 3 months).

Silk Road Medical: Today Best Nearby Cap-Gain Medical Equipment Stock Prospect

Silk Road Medical, Inc (NASDAQ:SILK ) Q4 2022 Results Conference Call February 28, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations Erica Rogers - Chief Executive Officer Lucas Buchanan - Chief Financial Officer and Chief Operating Officer Conference Call Participants Travis Steed - Bank of America Securities Robbie Marcus - JP Morgan Adam Maeder - Piper Sandler Joanne Wuensch - Citi Operator Good day, and thank you for standing by. Welcome to the Fourth Quarter 2022 Silk Road Medical Conference Call.

Silk Road Medical, Inc (SILK) Q4 2022 Earnings Call Transcript

SUNNYVALE, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months and full year ended December 31, 2022.

Silk Road Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Outlook

SUNNYVALE, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the fourth quarter and full year 2022 after market close on Tuesday, February 28th, 2023. Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Silk Road Medical to Report Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023

Silk Road Medical (SILK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

News for Silk Road Medical Inc Stock (SILK)